Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 09:02 ET | Source: Research and Markets

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
November 27, 2025 08:58 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:47 ET | Source: Research and Markets

CD73 Inhibitors Pipeline Report 2025: an Up-to-date Competitor Evaluation in the Field of Antibodies, RNA and Small Molecules in Research and Development Inhibiting CD73

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD73 Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about CD73 Inhibitors...
November 27, 2025 08:17 ET | Source: Research and Markets

C-Met-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of c-Met-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 25, 2025 10:01 ET | Source: Research and Markets

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
November 07, 2025 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

New translational data supports potential of NX-1607 as a novel next generation checkpoint inhibitor therapy
November 04, 2025 10:12 ET | Source: Research and Markets

Oncology Clinical Trials Market Research Report 2025 | Now Available

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The oncology clinical trials market size has...
October 22, 2025 10:44 ET | Source: Research and Markets

T-Cell Malignancies Pipeline Research Report 2025: Market Opportunities with Over 75 Companies and 80+ Drugs, Exploring Novel Treatments Like CAR-T Therapies and Targeted Therapies

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "T-Cell Malignancies - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers in-depth analysis of over 75...
October 21, 2025 05:34 ET | Source: Research and Markets

Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030" report has...
October 13, 2025 07:59 ET | Source: Research and Markets

Conjugated Drugs (XDCs) in Oncology Market Intelligence Tool Launched – Covering 2,500+ Pipeline Drugs and 1,300+ Funding Rounds

Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence" directory has been added to ...